A NOVEL STABILITY-INDICATING RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF ASPRIN, ATORVASTATIN AND CLOPIDOGREL IN CAPSULES

A novel stability-indicating, RP-HPLC method was developed for the simultaneous determination of the Aspirin, Atorvastatin and Clopidogrel in capsules. Chromatogram was run through BDS (150 mm X 4.6mm, 5μ). Mobile phase containing phosphate buffer pH 4.5 and acetonitrile in the ratio of (50:50, v/v) was pumped through column at a flow rate of 1ml/min. Optimized wavelength for Aspirin and Atorvastatin and Clopidogrel was 249 nm. Retention time of Aspirin, Atorvastatin and Clopidogrel were found to be 2.367 min, 5.463 min and 4.658 min, respectively. % RSD of the Aspirin, Atorvastatin and Clopidogrel were and found to be 1.01, 0.89 and 0.77 respectively. % recover was obtained as 99.79 %, 99.73 % and 100.57 % for Aspirin, Atorvastatin and Clopidogril, respectively. Limit of detection and quantification values are obtained from regression equations of Aspirin (0.8 ppm, 0.25 ppm), Atorvastatin (0.14 ppm, 0.41 ppm) and Clopidogrel (0.25 ppm, 0.76 ppm). Regression equation of Aspirin is y = 2433.x + 706.4, and of Atorvastatin is y = 17432x + 872.7and Clopidogrel is y = 2403.x + 412.3. The present method was performed the degradation studies like acid, base, oxidation, UV, thermal and neutral, results founds to be negligible. Key words: Aspirin, Atorvastatin, Clopidogrel, RP-HPLC and Estimation